Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of ramantamig versus teclistamab in relapsed or refractory multiple myeloma after 1-3 prior lines
MOH_2026-04-15_015768Phase 3Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ramantamig and teclistamab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
ramantamigteclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2026-04-15_015768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-04-15_015768.